#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis

Andrew R. Clamp, Jonathan A. Ledermann, Adrian Cook et al.|International Journal of Gynecological Cancer|2023

Cited by 4